Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: FBL Financial Group Schedules First Quarter 2013 Earnings Date, Conference Call and Webcast to FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain

This site contains about 58,903 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   100   200   300   400   520   530   540   550   560   570   580   590   600   608   609   610   611   612   613   614   615   616   617   618   619   620   621   622   623   624   625   626   627   628   629   630   631   632   633   634   635   636   637   640   650   660   670   680   690   700   710   720   800   900   1,000   1,100   1,200   1,300   1,400   1,500   1,600   1,964 

2013/4/11
FBL Financial Group Schedules First Quarter 2013 Earnings Date, Conference Call and Webcast
FBL Financial Group, Inc. (NYSE: FFG) will announce its first quarter 2013 earnings after the close of market on Thursday, May 2, 2013.
View more FBL Financial Group Schedules First Quarter 2013 Earnings Date, Conference Call and Webcast analysis
Sign-up for FBL Financial Group Schedules First Quarter 2013 Earnings Date, Conference Call and Webcast investment picks
2013/3/12
FBL Financial Group to Present at NYSSA Insurance Conference
FBL Financial Group, Inc. (NYSE: FFG) today announced that Richard J.
View more FBL Financial Group to Present at NYSSA Insurance Conference analysis
Sign-up for FBL Financial Group to Present at NYSSA Insurance Conference investment picks
2013/2/26
FBL Financial Group to Present at Raymond James Institutional Investors Conference
FBL Financial Group, Inc. (NYSE: FFG) today announced that Donald J.
View more FBL Financial Group to Present at Raymond James Institutional Investors Conference analysis
Sign-up for FBL Financial Group to Present at Raymond James Institutional Investors Conference investment picks
2013/3/7
FBL Licenses FAST for Life Policy Administration
FAST is announcing that FBL Financial Group, Inc. (NYSE: FFG) (“FBL”) has licensed FAST Insurance Components to serve as the core policy administration and new business system for its life insurance business.
View more FBL Licenses FAST for Life Policy Administration analysis
Sign-up for FBL Licenses FAST for Life Policy Administration investment picks
2013/2/5
FBR & Co. Announces 1-for-4 Reverse Stock Split
ARLINGTON, Va., Feb.
View more FBR & Co. Announces 1-for-4 Reverse Stock Split analysis
Sign-up for FBR & Co. Announces 1-for-4 Reverse Stock Split investment picks
2013/2/28
FBR & Co. Confirms Effectiveness of 1-for-4 Reverse Stock Split
ARLINGTON, Va., Feb.
View more FBR & Co. Confirms Effectiveness of 1-for-4 Reverse Stock Split analysis
Sign-up for FBR & Co. Confirms Effectiveness of 1-for-4 Reverse Stock Split investment picks
2013/4/23
FBR Reports First Quarter Financial Results
ARLINGTON, Va., April 23, 2013 (GLOBE NEWSWIRE) -- FBR & Co.
View more FBR Reports First Quarter Financial Results analysis
Sign-up for FBR Reports First Quarter Financial Results investment picks
2013/2/5
FBR Reports Fourth Quarter and Full Year 2012 Financial Results
ARLINGTON, Va., Feb.
View more FBR Reports Fourth Quarter and Full Year 2012 Financial Results analysis
Sign-up for FBR Reports Fourth Quarter and Full Year 2012 Financial Results investment picks
2013/4/9
FBR to Report First Quarter 2013 Financial Results
ARLINGTON, Va., April 9, 2013 (GLOBE NEWSWIRE) -- FBR & Co.
View more FBR to Report First Quarter 2013 Financial Results analysis
Sign-up for FBR to Report First Quarter 2013 Financial Results investment picks
2013/2/6
FCC Hopes to Create "Super WiFi" Networks that Will Provide Free Wireless Internet to the Public
http://media.marketwire.com/attachments/201212/107982_FSE_Logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=982556&ProfileId=051205&sourceType=1 NEW YORK, NY --
View more FCC Hopes to Create "Super WiFi" Networks that Will Provide Free Wireless Internet to the Public analysis
Sign-up for FCC Hopes to Create "Super WiFi" Networks that Will Provide Free Wireless Internet to the Public investment picks
2013/5/8
FCC Likely to Consider Using Satellite Airwaves for In-Flight Internet
WASHINGTON --In-flight Internet speeds could rival those on the ground under a proposal expected to move forward on Thursday.
View more FCC Likely to Consider Using Satellite Airwaves for In-Flight Internet analysis
Sign-up for FCC Likely to Consider Using Satellite Airwaves for In-Flight Internet investment picks
2013/2/7
FCC Plan for Free Public WiFi Gains Traction After Endorsements From Google and Microsoft
http://media.marketwire.com/attachments/201212/107982_FSE_Logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=983063&ProfileId=051205&sourceType=1 NEW YORK, NY --
View more FCC Plan for Free Public WiFi Gains Traction After Endorsements From Google and Microsoft analysis
Sign-up for FCC Plan for Free Public WiFi Gains Traction After Endorsements From Google and Microsoft investment picks
2013/3/22
FCE Bank's 2012 Annual Report and Accounts Publication is Now Available
DEARBORN, Mich.
View more FCE Bank's 2012 Annual Report and Accounts Publication is Now Available analysis
Sign-up for FCE Bank's 2012 Annual Report and Accounts Publication is Now Available investment picks
2013/3/4
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B
Biogen Idec (NASDAQ: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B and granted the company a standard review timeline.
View more FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B analysis
Sign-up for FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B investment picks
2013/4/17
FDA Advisory Committee Recommends Approval of BREO(TM) ELLIPTA(TM) for the Treatment of COPD
http://media.marketwire.com/attachments/201212/55322_gsklogo.jpg http://media.marketwire.com/attachments/201210/52482_theravance_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1008302&ProfileId=051205&sourceType=1 LONDON and SOUTH SAN FRANCISCO, CA --
View more FDA Advisory Committee Recommends Approval of BREO(TM) ELLIPTA(TM) for the Treatment of COPD analysis
Sign-up for FDA Advisory Committee Recommends Approval of BREO(TM) ELLIPTA(TM) for the Treatment of COPD investment picks
2013/4/17
FDA Advisory Committee recommends approval of BREO™ ELLIPTA™ for the treatment of COPD
LONDON and SOUTH SAN FRANCISCO, Calif.
View more FDA Advisory Committee recommends approval of BREO™ ELLIPTA™ for the treatment of COPD analysis
Sign-up for FDA Advisory Committee recommends approval of BREO™ ELLIPTA™ for the treatment of COPD investment picks
2013/5/2
FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA™ XC as a Safe and Effective Treatment Option for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face
Allergan, Inc., (NYSE: AGN) is pleased that the U.S. Food and Drug Administration (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee has voted unanimously that the benefits of JUVÉDERM VOLUMA™ XC, an injectable hyaluronic acid dermal filler for cheek augmentation to correct age-related volume deficit in the mid-face, outweigh the risks.
View more FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA™ XC as a Safe and Effective Treatment Option for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face analysis
Sign-up for FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA™ XC as a Safe and Effective Treatment Option for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face investment picks
2013/3/20
FDA Advisory Committee Votes Favorably on Abbott's Minimally Invasive MitraClip® Device for Patients with Significant Mitral Regurgitation Who Are Too High Risk for Surgery
ABBOTT PARK, Ill., March 20, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of treatment with the MitraClip ® device outweigh its risks in patients with significant symptomatic mitral regurgitation (MR) who have been determined by a cardiac surgeon to be too high risk for open mitral valve surgery and in whom existing co-morbidities would not preclude the expected benefit from correction of the MR.
View more FDA Advisory Committee Votes Favorably on Abbott's Minimally Invasive MitraClip® Device for Patients with Significant Mitral Regurgitation Who Are Too High Risk for Surgery analysis
Sign-up for FDA Advisory Committee Votes Favorably on Abbott's Minimally Invasive MitraClip® Device for Patients with Significant Mitral Regurgitation Who Are Too High Risk for Surgery investment picks
2013/2/12
FDA Advisory Committee Votes in Favour of Cangene's Botulism Antitoxin Product
FDA Advisory Committee Votes in Favour of Cangene's Botulism Antitoxin Product Canada NewsWire Readers are referred to the cautionary notes regarding Forward-looking Information and non-IFRS Financial Measures at the end of this release.
View more FDA Advisory Committee Votes in Favour of Cangene's Botulism Antitoxin Product analysis
Sign-up for FDA Advisory Committee Votes in Favour of Cangene's Botulism Antitoxin Product investment picks
2013/2/15
FDA Approved a Total of 39 New Drugs in 2012 - Fifteen Year High
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=986372&ProfileId=051205&sourceType=1 NEW YORK, NY --
View more FDA Approved a Total of 39 New Drugs in 2012 - Fifteen Year High analysis
Sign-up for FDA Approved a Total of 39 New Drugs in 2012 - Fifteen Year High investment picks
2013/2/5
FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=981955&ProfileId=051205&sourceType=1 NEW YORK, NY --
View more FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High analysis
Sign-up for FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High investment picks
2013/2/1
FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=980935&ProfileId=051205&sourceType=1 NEW YORK, NY --
View more FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High analysis
Sign-up for FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High investment picks
2013/2/13
FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=985188&ProfileId=051205&sourceType=1 NEW YORK, NY --
View more FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High analysis
Sign-up for FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High investment picks
2013/2/11
FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High
http://media.marketwire.com/attachments/201301/56000_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=983989&ProfileId=051205&sourceType=1 NEW YORK, NY --
View more FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High analysis
Sign-up for FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High investment picks
2013/2/20
FDA Approves Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market the Natrelle ® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.
View more FDA Approves Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants analysis
Sign-up for FDA Approves Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants investment picks
2013/4/22
FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
ROCKVILLE, Md.
View more FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder analysis
Sign-up for FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder investment picks
2013/3/29
FDA Approves New Drug Application (NDA) for Teva’s Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy
Teva Pharmaceutical Industries Ltd.
View more FDA Approves New Drug Application (NDA) for Teva’s Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy analysis
Sign-up for FDA Approves New Drug Application (NDA) for Teva’s Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy investment picks
2013/4/30
FDA Approves Over-The-Counter Availability of Plan B One-Step® (levonorgestrel) tablet 1.5 mg for Consumers 15 and Over
Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd.
View more FDA Approves Over-The-Counter Availability of Plan B One-Step® (levonorgestrel) tablet 1.5 mg for Consumers 15 and Over analysis
Sign-up for FDA Approves Over-The-Counter Availability of Plan B One-Step® (levonorgestrel) tablet 1.5 mg for Consumers 15 and Over investment picks
2013/4/23
FDA Approves Second Drug in BD Simplist™ Prefilled Injectable Line of Products
Approval Follows Recent Launch of Generic Prefilled Injectables FRANKLIN LAKES, N.J. , April 23, 2013 /PRNewswire/ -- BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE:BDX) , announced today that the U.S. Food and Drug Administration (FDA) has approved the second drug to be offered in the recently launched BD Simplist™  line of ready-to-administer prefilled generic injectables.
View more FDA Approves Second Drug in BD Simplist™ Prefilled Injectable Line of Products analysis
Sign-up for FDA Approves Second Drug in BD Simplist™ Prefilled Injectable Line of Products investment picks
2013/4/23
FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Sucampo’s supplemental new drug application (sNDA) for AMITIZA ® (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.
View more FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain analysis
Sign-up for FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: FBL Financial Group Schedules First Quarter 2013 Earnings Date, Conference Call and Webcast to FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.